13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BMS CA209-7A8

    Acronym: 

    BMS CA209-7A8

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II Tumour Stream Breast
    Age Range Post-menopausal Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase II
    Age Range Post-menopausal
    Sex Female
    Molecular Target
    Tumour Stream Breast
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    Randomized, non-comparative neoadjuvant phase II study in postmenopausal women with stage II-III, ER+/HER2-Breast cancer with safety run-in, assessing nivolumab+ abemaciclibor palbociclib+ anastrozole

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Dr Rohit Joshi Not Yet Recruiting